Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

MTX-211

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Mekanistic Therap

Drug class:

EGFR inhibitor, PI3K inhibitor

Related drugs:

‹

inhibitors of the PI3K/AKT/mTOR pathway (0)

cetuximab (347)

osimertinib (301)

erlotinib (235)

gefitinib (194)

panitumumab (123)

lapatinib (107)

neratinib (102)

brigatinib (50)

amivantamab-vmjw (25)

firmonertinib (14)

mobocertinib (12)

lazertinib (12)

tarloxotinib bromide (7)

nimotuzumab (6)

rociletinib (5)

tomuzotuximab (4)

necitumumab (3)

befotertinib (3)

sunvozertinib (3)

zorifertinib (3)

ABP 494 (cetuximab biosimilar) (1)

Compound 6a (1)

abivertinib (1)

sevabertinib (1)

STI-001 (cetuximab biosimilar) (0)

antroquinonol (0)

zalutumumab (0)

JNJ-26483327 (0)

asandeutertinib (0)

PF-08046052 (0)

rindopepimut (0)

amivantamab and hyaluronidase-lpuj (0)

Undisclosed EGFR inhibitor (0)

cetuximab biosimilar (0)

PF-06747775 (0)

JNJ-64041757 (0)

PF-05212384 (31)

GSK2126458 (17)

PF-04691502 (6)

enzastaurin (3)

BAY 1082439 (1)

inhibitors of the PI3K/AKT/mTOR pathway (0)

›